SCHEMBL10165548

SCHEMBL10165548

Cc1cccc2c1ccn2C(CC(C)C)C(=O)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
FABP4 P15090 2/20 0.38
EZH2 Q15910 1/20 0.35
ANPEP P15144 2/20 0.34
ATM Q13315 2/20 0.33
PRMT5 O14744 1/20 0.32
NTSR1 P30989 1/20 0.32
NR3C2 P08235 1/20 0.31
CYP24A1 Q07973 1/20 0.31
MAPT P10636 1/20 0.31
F2R P25116 1/20 0.31
SLC6A3 Q01959 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10165539 0.82 HTR2A (0.42) HTR2AHTR2CSLC6A2SLC6A4FABP4
SCHEMBL31560786 0.72 HTR2A (0.45) HTR2AHTR2CSLC6A2SLC6A4FABP4
SCHEMBL16234663 0.71 NR3C2 (0.46) HTR2AHTR2CSLC6A2SLC6A4FABP4
SCHEMBL13090965 0.70 HTR2C (0.53) HTR2AHTR2CSLC6A2SLC6A4FABP4
SCHEMBL31560728 0.70 HTR2A (0.44) HTR2AHTR2CSLC6A2SLC6A4FABP4
SCHEMBL10165552 0.68 HTR2A (0.51) HTR2AHTR2CFABP4PRMT5KDM4E
SCHEMBL23714707 0.67 HTR2A (0.49) HTR2AHTR2CSLC6A2SLC6A4FABP4
SCHEMBL10165567 0.66 FABP4 (0.44) HTR2AHTR2CFABP4PRMT5NR3C2
SCHEMBL11573644 0.62 NOTUM (0.67) HTR2AHTR2CFABP4KDM4EALDH1A1
SCHEMBL5623104 0.62 NOTUM (0.49) HTR2AHTR2CFABP4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883766-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-11-11 US disclosed
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-16 US disclosed
US-8193194-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208790-A1 ION CHANNEL MODULATORS AND METHODS OF USE CACNA1G, CACNA1C, CACNA1B HTR2A 720/4885HTR2C 901/4885SLC6A2 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.